Douglas Brawley, PhD
About Douglas Brawley, PhD
Douglas Brawley, PhD, is a Business Development Manager at NYU Langone Health, managing a portfolio of over 150 inventions and collaborating with the Technology Opportunities & Ventures Team to commercialize biomedical inventions.
Title at NYU Langone Health
Since 2021, Douglas Brawley, PhD, has served as the Business Development Manager at NYU Langone Health in New York, United States. In this role, he strategically manages a portfolio of over 150 inventions from more than 100 NYU faculty members across three NYU campuses. Brawley collaborates closely with the Technology Opportunities & Ventures Team to commercialize early-stage biomedical inventions.
Previous Role at NYU Langone Health
From 2018 to 2020, Douglas Brawley was an intern at Therapeutics Alliances (TA) within NYU Langone Health. During his internship, he gained crucial experience and insights that have been instrumental in his current role as Business Development Manager. This period paved the way for his deeper engagement with academic-industry relationships and technology commercialization.
Educational Background and Expertise in Finance and Molecular Biophysics
Douglas Brawley holds a Doctor of Philosophy (PhD) in Molecular Biophysics (Structural Biology) from NYU Grossman School of Medicine, where he studied from 2014 to 2021. Brawley has also pursued studies in finance at NYU Stern School of Business, having courtesy audited select courses in 2018. Furthermore, he holds a B.S. degree in Biology with a minor in Chemistry from the University of North Carolina Asheville, completed between 2008 and 2013. Starting in Fall 2024, he will begin coursework in UC Berkeley Haas’ Part-time MBA program.
Experience in Academic-Industry Relationships
Douglas Brawley has extensive experience in drafting, negotiating, and concluding various partnership agreements standard to academic-industry relationships. His work has involved launching over 50 active marketing campaigns for NYU technologies. His strategic approach ensures effective commercialization of biomedical inventions, reflecting a deep understanding of both scientific research and financial principles.